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Background: Abiraterone acetate (AA) is widely used in the treatment of patients with 
metastatic castration-resistant prostate cancer (mCRPC). However, a significant percentage 
of patients will still progress, highlighting the need to identify patients more likely to benefit 
from AA. Parameters linked to prostate-specific antigen (PSA) kinetics are promising 
prognostic markers. We have examined clinical and PSA-related factors potentially asso-
ciated with overall survival (OS) in patients treated with AA.
Methods: Between 2011 and 2014, 104 patients with mCRPC treated with AA after 
progression to docetaxel at centers of the Catalan Institute of Oncology were included in 
this retrospective study. Patients were assessed monthly. Baseline characteristics and vari-
ables related to PSA kinetics were included in univariate and multivariate analyses of OS.
Results: Median OS was 16.4 months (range 12.4–20.6) for all patients. The univariate 
analysis identified the following baseline characteristics as significantly associated with OS: 
ECOG PS, location of metastases, time between starting androgen deprivation therapy and 
starting AA, time between stopping docetaxel treatment and starting AA, neutrophil- 
lymphocyte ratio (NLR), alkaline phosphatase levels, and PSA levels. Factors related to 
PSA kinetics associated with longer OS were PSA response >50%, early PSA response 
(>30% decline at four weeks), PSA decline >50% at week 12, PSA nadir <2.4ng/mL, time to 
PSA nadir >140 days, the combination of PSA nadir and time to PSA nadir, and low end-of- 
treatment PSA levels. The multivariate analysis identified ECOG PS (HR 37.46; p<0.001), 
NLR (HR 3.7; p<0.001), early PSA response (HR 1.22; p=0.002), and time to PSA nadir 
(HR 0.39; p=0.002) as independent prognostic markers.
Conclusion: Our results indicate an association between PSA kinetics, especially early PSA 
response, and outcome to AA after progression to docetaxel. Taken together with other 
factors, lack of an early PSA response could identify patients who are unlikely to benefit 
from AA and who could be closely monitored with a view to offering alternative therapies.
Keywords: castration-resistant prostate cancer, abiraterone, PSA kinetics, survival, early 
PSA response
Introduction
The treatment armamentarium of metastatic castration-resistant prostate cancer 
(mCRPC) has increased in recent years with the FDA/EMA approval of hormonal 
therapies like abiraterone acetate (AA) and enzalutamide, cytotoxic therapies like 
cabazitaxel,1 and bone-targeted therapies like Radium-223.2,3 Given the increase in 
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treatment options for mCRPC, the selection of optimal 
therapeutic regimens is crucial for obtaining the maximum 
survival benefit.2,4 Predictive biomarkers of response can 
help in the selection of an effective treatment while avoid-
ing unnecessary toxicities and excess costs associated with 
a potentially ineffective drug.
AA is a prodrug of abiraterone and is a selective, 
irreversible inhibitor of the androgen biosynthesis enzyme 
CYP17, which is involved in androgen production in the 
testes, adrenal glands and prostate tumor tissue. AA in 
combination with prednisone has demonstrated an increase 
in overall survival (OS) in patients with mCRPC and is 
approved for patients who progress during or after doce-
taxel-based chemotherapy,5 in chemotherapy-naïve 
patients,6 and in metastatic castration-sensitive patients.7 
However, approximately one-third of treated patients show 
primary resistance to AA,6 highlighting the need for early 
identification of these patients in order to offer them an 
alternative therapy before progression-related clinical 
deterioration renders them ineligible for subsequent ther-
apy, including chemotherapy.
Several studies have suggested a relationship between 
decrease in prostate-specific antigen (PSA) levels and sur-
vival, mainly in chemotherapy treated mCRPC patients.5 
However, the role of PSA decline as a surrogate marker of 
survival in patients treated with hormonal therapies has not 
been clearly established. Biosynthesis of extragonadal 
androgens may contribute to progression in mCRPC, 
which still depends on androgen receptor signals, and 
a relationship between PSA kinetics and response to AA 
has been suggested,8 indicating that PSA kinetics may be 
a useful predictive biomarker of response.2
In order to shed further light on the potential associa-
tion of baseline patient characteristics and PSA kinetics 
with OS, we have performed a retrospective study of 104 
mCRPC patients treated with AA after progression to 
docetaxel.
Patients and Methods
Study Design and Patient Population
This was a retrospective observational study that included 
104 mCRPC patients treated at three centers of the Catalan 
Institute of Oncology (University Hospital of Germans 
Trias i Pujol, Badalona; Bellvitge University Hospital, 
l’Hospitalet de Llobregat; and University Hospital of 
Girona Doctor Josep Trueta, Girona) from August 2011 
to October 2014. All patients had histologically confirmed 
prostate adenocarcinoma with evidence of metastatic dis-
ease and all had been previously treated with docetaxel. 
Patients received AA 1000mg orally once daily plus pre-
dnisone 5mg twice daily. Each treatment cycle was 28 
days. Treatment was continued until disease progression 
according to the Prostate Cancer Working Group 2 
(PCWG2) criteria,9 death, or unacceptable toxicity.
During treatment with AA, patients were assessed 
every four weeks. Clinical visits included a physical exam-
ination and routine laboratory analyses, including PSA 
levels, albumin, alkaline phosphatase (ALP) levels, neu-
trophil and lymphocyte counts, and hemoglobin levels. 
Thoracic-abdominopelvic computed tomography (CT) 
and/or a bone scan were performed before starting AA 
therapy and during the treatment period in accordance 
with the protocols of each center.
The following baseline variables were recorded and 
patients classified accordingly: age (<74 vs ≥74 years), 
Eastern Cooperative Oncology Group (ECOG) performance 
status (PS) (0 vs 1 vs 2), number of previous lines of che-
motherapy (1 vs ≥2), metastatic sites (bone only vs lymph 
node only vs bone and lymph nodes vs visceral), Gleason 
score (≤7 vs 8–10), neutrophil-to-lymphocyte ratio (NLR) 
(≤4 vs >4), hemoglobin levels (<10 gr/dl vs ≥10 gr/dl), ALP 
levels (≤upper limit of normality [ULN] vs >ULN), PSA 
levels (classified by terciles), PSA doubling time (PSADT) 
(≤3 months vs >3 months), interval between starting andro-
gen deprivation therapy and starting AA (≤20 months vs >20 
months), interval between stopping docetaxel therapy and 
starting AA (≤3 months vs >3 months), and type of progres-
sion (PSA progression vs radiographic progression vs clin-
ical deterioration). PSADT was calculated with the Memorial 
Sloan Kettering online calculator. NLR was the ratio of the 
absolute neutrophil count divided by the absolute lympho-
cyte count.
The following data regarding PSA kinetics were 
recorded during AA treatment: PSA response (>50% vs 
<50%); early PSA response, defined as the percentage of 
PSA decline at week 4 (decline ≥30% vs decline <30% or 
increase <20% vs increase >20%); PSA response at week 
12 (>50% vs <50%); PSA nadir (≥2.4 ng/mL vs <2.4 ng/ 
mL); time to PSA nadir; and end-of-treatment (EOT) PSA 
levels, defined as the levels at the last PSA assessment 
during AA treatment (classified by terciles).
Statistical Analyses
Data were recorded with Microsoft Excel 2007 and statis-
tical analyses were carried out using R v3.6.0. We built 
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a multivariate model starting with all untransformed vari-
ables after excluding those exceeding 15% of individuals 
(for which there were insufficient numbers of observa-
tions). Data were imported from Excel into R with the 
readxl R package. Prior to analysis, data wrangling and 
cleaning was performed with the tidyverse suite of 
packages (including dplyr, purr, lubridate, stringr, and 
broom). Descriptive statistics including missing data 
were collected and visualized with the skimr and rms 
R packages. Data were described in terms of ranges, 
medians, frequencies, and percentages. OS was defined 
as the time from the start of AA treatment to death from 
any cause. Data were censored at the time of patient death. 
Optimal cut-off points for possible categorical transforma-
tions were identified with the survminer R package. 
A univariate analysis was performed to determine the 
association of different factors with OS and Kaplan 
Meier plots were generated using the survival R package. 
Due to limitations in sample size, not all variables identi-
fied as significant in the univariate analysis could be 
included in the multivariate analysis. After imputing miss-
ing data with the Hmisc R package, a variable selection 
strategy was followed based on elastic net Cox propor-
tional hazards model fitting via penalized maximum like-
lihood, using the glmnet R package. This was followed by 
AIC maximization stepwise backward variable elimination 
towards model reduction. All models generated on 
imputed data were tested against intact data. An internal 
cross-validation was performed by bootstrapping with 200 
iterations. Imputation, Cox modeling, stepwise model 
selection and model validation, were done using the rms 
R package. Recursive tree partitioning was explored using 
the party R package. Significance was set at p≤0.05.
Results
Patient Characteristics and Treatment
The main patient characteristics are detailed in Table 1. Median 
age was 74 years (range, 49–86), 82% of patients had ECOG 
PS 0–1, and 51.9% had a Gleason score ≥8. Bone metastases 
were present in 49% of the patients, while 11.6% had only 
lymph node metastases and 9.7% had visceral metastases. All 
patients had previously been treated with docetaxel and 32% 
had received two or more prior chemotherapy regimens.
Median duration of treatment was 7.85 months (range, 
1–52 months). At the time of this analysis, 96 patients 
(92%) had died. Median OS was 16.4 months (95% con-
fidence interval [CI] 12.2–20.6) for all patients (Figure 1A) 
and 1-year and 2-year survival rates were 66% and 33%, 
respectively. Median progression-free survival was 7.8 
months (95% CI 5.9–9.6) (Figure 1B).
Table 1 Baseline Patient Characteristics
Characteristic N (%)
Age
< 74 y 54 (51.9)
≥ 74y 50 (48.1)







≥ 8 54 (51.9)
Not available 15 (14.4)
Location of metastases
Lymph node only 12 (11.6)
Bone only 51 (49)
Bone and lymph node 30 (28.8)
Visceral 10 (9.7)
Not available 1 (0.9)








≥10 g/dL 20 (19.3)






Not available 6 (5.8)
Median (range) 183.07 (0.98–1127)




Not available 1 (0.9)
Median ng/mL (range) 284.6 (0.5–6947)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance 
status; NLR, neutrophil-to-lymphocyte ratio; ALP, alkaline phosphatase; PSA, pros-
tate-specific antigen.
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Baseline Characteristics and OS
In the univariate analysis, the following baseline char-
acteristics were associated with longer OS: ECOG PS 
<2 (p<0.001) (Figure 2A); only lymph node metastases 
(p=0.04); interval between starting androgen depriva-
tion therapy and starting AA ≥20 months (p=0.006); 
interval between stopping docetaxel and starting AA 
≥3 months (p=0.04); NLR <4 (p<0.001) (Figure 2B); 
ALP levels ≤ULN (p=0.03); and low/intermediate PSA 
levels (p<0.001). No other significant association 
between baseline characteristics and OS was observed 
(Table 2).
Prognostic Impact of PSA Kinetics
Table 3 shows the univariate analysis of OS according to 
factors related to PSA kinetics. PSA response >50% 
(p<0.001), early PSA response ≥30% (p=0.01; Figure 3), 
PSA response >50% at week 12 (p<0.001), PSA nadir 
<2.4ng/mL (p<0.001), time to PSA nadir >140 days 
(p<0.001), and low EOT PSA levels (p<0.001) were asso-
ciated with longer OS. In addition, we observed 
a combinatory effect for PSA nadir plus time to PSA 
nadir, where patients with lower PSA nadir and longer 
time to PSA nadir had the longest OS (hazard ratio [HR] 
0.57; 95% CI 1.43–1.75; p< 0.001) (Figure 4).
The multivariate analysis identified ECOG PS (HR 
37.46; p<0.001), NLR (HR 3.7; p<0.001), early PSA 
response (HR 1.22; p=0.002), and time to PSA nadir 
(HR 0.39; p=0.002), as independent markers of OS 
(Table 4). Based on these findings, we generated 
a decision tree for survival analysis in mCRPC, which 
indicated that baseline ECOG PS and NLR combined 
could predict OS (Figure 5).
Discussion
Several treatment options are now available for mCRPC. 
Novel hormonal therapies, including AA, have demon-
strated activity in patients previously treated with doce-
taxel, but other therapies, such as cabazitaxel1 or radium- 
223,3 can be useful in patients refractory to 
hormonal therapies. Primary resistance to AA in pre- 
docetaxel mCRPC patients is near 20%, and the identifica-
tion of patients with primary resistance may help avoid 
ineffective treatments.10 In the present study, we have 
examined the impact on OS of several baseline character-
istics and parameters related to PSA kinetics in patients 
with mCRPC treated with AA. The multivariate analysis 
identified two baseline characteristics (ECOG PS and 
NLR) and two variables associated with PSA kinetics 
(early PSA response and time to PSA nadir) as indepen-
dent markers of OS.
Our patients were treated off-study, yet OS was within 
the range of that reported in the COU-AA-302 trial,11 
despite the fact that a higher percentage of our patients 
had PS 2 (17% vs 10%). In the COU-AA-301 trial,12 
ECOG PS >1, presence of liver metastases, time between 
starting androgen deprivation therapy and starting AA >36 
months, low serum albumin, and high serum ALP and 
LDH levels were associated with a poorer outcome to 
AA.13 Our findings regarding ECOG PS, time between 
Figure 1 (A) Overall survival and (B) progression-free survival from the start of 
abiraterone acetate treatment for all 104 patients.
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starting androgen deprivation therapy and starting AA, and 
ALP levels were in line with these results. In addition, 
however, we found that low NLR, low baseline PSA 
levels, the absence of bone metastases, and high hemoglo-
bin levels were also associated with longer OS.
NLR is a marker of inflammation and immune status 
related to carcinogenesis, and its role as a potential prog-
nostic and predictive marker has been evaluated in many 
solid tumors, including mCRPC. In a study carried out at 
the Princess Margaret Cancer Centre,14 NLR ≥5 was sig-
nificantly associated with PSA response and survival in 
116 patients with mCRPC treated with AA, 53% of whom 
had previously been treated with docetaxel. NLR has also 
been identified as a prognostic marker in patients with 
mCRPC treated with second-line chemotherapy.15 
Furthermore, a persistent NLR <3 during treatment with 
enzalutamide was associated with greater treatment effi-
cacy in patients with mCRPC.16 Taken together with these 
previous results, our finding in the present study that 
a high NLR was related to shorter OS suggests that NLR 
is a promising prognostic marker and leads us to postulate 
that NLR in combination with ECOG PS can be a useful 
prognostic marker in patents with mCRPC. Whereas in 
patients with PS 0 and PS 2, survival is well defined, in 
the intermediate group of patients with PS 1, NLR can be 
useful in selecting which patients are likely to benefit from 
AA, especially as NLR assessment can easily be incorpo-
rated into routine clinical practice.
In contrast, age and Gleason score were not associated 
with OS. In fact, AA has demonstrated activity in mCRPC 
regardless of patient age,5 and several studies have found 
that Gleason score may well lose prognostic impact in 
heavily pretreated mCRPC patients.13,17–19 Additionally, 
the number of prior chemotherapy lines was not associated 
with OS. More than 50% of our patients who had received 
a second line of chemotherapy before AA were treated 
with docetaxel, in accordance with common practice at 
that time, and the interval between ending docetaxel and 
starting AA was more highly associated with OS than the 
number of previous lines.
The prognosis of mCRPC patients ranges from a few 
months to several years and is influenced by multiple 
factors. Several studies have identified predictive bio-
markers of resistance to hormonal therapies. For exam-
ple, Wnt pathway genes have been associated with 
resistance to AA20 and baseline circulating tumor cell 
counts have also shown promise as prognostic 
markers.21 Our findings on PSA kinetics can further 
refine these biomarker-based data and can be used in 
routine clinical practice to identify patients likely to be 
resistant to AA.
PSA nadir and time to PSA nadir were also associated 
with OS in our study. Previous studies have also reported 
the impact of these factors on OS, in both chemotherapy- 
and hormonotherapy-treated patients.22–24 Along these 
same lines, our univariate analysis revealed an association 
Figure 2 Overall survival according to (A) ECOG PS and (B) NLR.
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between PSA nadir and time to PSA nadir with OS. This 
effect may be due to stroma-epithelial interactions and 
“tumor regulating fibroblasts”, which are now being stu-
died with promising results in vitro and in vivo.25
Several studies have found that PSA decline can be 
a marker of response to treatment and of longer OS,17,26–30 
since PSA levels reflect disease burden. In two Phase III 
trials of AA – in chemotherapy-pretreated5 and in che-
motherapy-naïve13 patients – PSA kinetics were signifi-
cantly associated with survival.31 In our study, we also 
observed that PSA kinetics could predict the efficacy of 
treatment with AA. Importantly, we found a relationship 
between early PSA response and OS. This finding is in 
line with previous retrospective studies carried out in 
a limited number of patients, where early PSA changes 
were associated with response and survival to AA and 
enzalutamide. In a study of patients treated with enzaluta-
mide after docetaxel, a PSA increase >20% at week 4 was 
associated with shorter progression-free survival and OS, 
while a PSA decline >30% was only associated with 
progression-free survival but not OS.32 In a study of 
patients treated with AA before or after docetaxel, PSA 
decline at week 4 was significantly associated with 
response at week 12 and with longer OS, both in patients 
who had previously received docetaxel as well as in che-
monaive patients.33 Furthermore, Facchini et al reported 
that a very early PSA response (>50% decline at day 15 of 
AA treatment) was associated with longer progression-free 
survival and OS.8 Finally, Caffo et al found that patients 
treated with AA or enzalutamide who did not show a PSA 
decline >50% at four weeks had a 50% risk of progression 
within three months, compared to an 18% risk for patients 
with an early PSA response.6,34 The ability to predict the 
efficacy of AA at an early time point can be crucial in 
patient management, since this allows a prompt change in 
treatment strategy, preventing clinical deterioration which 
can hinder the administration of subsequent therapies. At 
present, the majority of physicians switch therapy based 
on clinical progression,35 and while the absence of early 
PSA response may not in itself be a sufficient rationale for 
changing therapy, it will help identify those patients who 
require closer monitoring.
Several studies have suggested prognostic models in 
mCRPC. Halabi et al36 classified patients in a clinical 
trial into high- and low-risk groups based on several 
baseline characteristics, while Armstrong et al37 devel-
oped a risk classification scheme based on pain, visceral 
metastases, anemia, and bone scan progression that was 











< 74 years 20.28 15.39–27.75
≥ 74 years 13.68 11.21–21.21





Location of metastases 0.043
Lymph node only 34.41 22.92-NR
Bone only 14.83 13.48–21.44





Time between starting 
androgen deprivation 
therapy and starting AA
0.006
<20 months 9.37 8.02-NR
≥20 months 16.9 14.4–21.99
Time between stopping 
docetaxel and starting AA
0.04
<3 months 12.26 7.17–21.21





<10 g/dL 11.56 9.21–21.21




PSA levels by terciles <0.001
Low (≤54 ng/mL) 21.35 13.64–39.32
Intermediate (54–293 ng/mL) 21.21 16.47–28.41
High (>293 ng/mL) 11.9 8.91–17.56
Note: *Significant p-values are shown in bold. 
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance 
status; NLR, neutrophil-to-lymphocyte ratio; LDH, lactate dehydrogenase; ALP, 
alkaline phosphatase; ULN, upper limit of normal; PSA, prostate-specific antigen; 
NR, not reached.
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able to predict 30% PSA decline. Based on our findings 
in the present study, we propose a decision tree for 
survival analysis based on the variables of ECOG PS 
and NLR, both of which are easily collected from all 
patients. We plan to test the validity of our proposal in 
future studies.
Table 3 Univariate Analysis of Overall Survival (OS) According to Prostate-Specific Antigen (PSA) Kinetics
Parameter N (%) Median OS (Months) 95% CI p-value
PSA response >50% <0.001
No 52 (50) 12.36 9.21–16.47
Yes 52 (50) 22.06 18.08–28.41
Early PSA response (at week 4)* 0.012
≥30% decrease 45 (43.3) 21.53 18.08–28.41
<30% decrease or <20% increase 18 (17.3) 14.25 8.12–28.34
>20% increase 33 (31.7) 13.48 8.91–20.28
PSA response at week 12* <0.001
>50% 36 (34.6) 25.35 20.38–28.67
<50% 15 (14.4) 12.97 9.47–16.47
PSA nadir* <0.001
≥2.4 ng/mL 69 (66.3) 14.66 12.16–19.33
<2.4ng/mL 17 (16.3) 30.87 21.99-NR
Time to PSA nadir* <0.001
≤140 days 53 (51) 13.64 10.65–16.47
>140 days 22 (21.1) 28.34 22.06–46.82
EOT PSA* <0.001
Low (≤54 ng/mL) 39 (37.5) 25.35 20.71–29.49
Intermediate (54–293 ng/mL) 42 (40.4) 16.68 13.68–24.33
High (>293 ng/mL) 22 (21.2) 10.08 7.2–16.27
Note: *Details of PSA kinetics were not available for all patients. 
Abbreviations: EOT, end of treatment; NR, not reached.
Figure 4 Overall survival according to PSA nadir plus time to PSA nadir.Figure 3 Overall survival according to early PSA response (at week 4).
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As with all retrospective studies, our results must be inter-
preted with caution and should be validated in prospective 
studies including a larger number of patients. Our study has 
several limitations, such as the limited number of patients 
included and a number of patients with some missing data. 
Despite these limitations, however, our findings indicate that 
NLR can be a useful baseline marker to predict outcome in 
patients with mCRPC treated with AA and that early PSA 
response to AA may be a useful marker of treatment efficacy. 
While an early change in PSA is generally not a sufficient 
reason for modifying treatment in clinical trials,9 we propose to 
closely monitor patients with an early PSA increase during AA 
treatment, as well as taking into account other prognostic and 
predictive markers, when deciding on next treatment options.
Patient Consent
For this type of study, formal consent is not required.
Data Sharing Statement
Supporting data for this study is freely available upon 
request to the corresponding author.
Ethics Approval
This study was approved by the Ethics Committees of the 
Catalan Institute of Oncology at University Hospital of 
Germans Trias i Pujol (PI 16-183). This approval covers 
all three centers of the Catalan Institute of Oncology. The 
study was performed in accordance with the ethical stan-
dards laid down in the 1964 Declaration of Helsinki and its 
later amendments. All patient data were anonymized and 
Figure 5 Decision tree for survival of prostate cancer patients, showing ECOG PS and NLR at the beginning of abiraterone acetate treatment.
Table 4 Multivariate Analysis of Overall Survival






1 3.30 (1.54–7.09) 0.002
2 37.46 (10.77–130.21) <0.001
NLR
<4 1.00 (Ref)
≥4 3.70 (1.77–7.74) <0.001
PSA Kinetics
Early PSA response (at 
week 4)
Response 1.00 (Ref)
No response 1.22 (1.07–1.38) 0.002
Time to PSA nadir
≤140 days 1.00 (Ref)
≥140 days 0.39 (0.21–0.73) 0.002
Abbreviations: NLR, neutrophil-to-lymphocyte ratio; PSA, prostate-specific 
antigen.
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codified to ensure adequate compliance with the Spanish 
Data Protection Law 15/1999 and Royal Decree-Law 5/ 
2018 of 27 July on urgent measures for the adaptation of 
Spanish law to European Union regulations on data pro-
tection. All data are stored in the Medical Oncology 
Service of the ICO-Badalona, Germans Trias i Pujol 
University Hospital.
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